Drug interactions: Proteins, pumps, and P-450s

被引:58
作者
Shapiro, LE
Shear, NH
机构
[1] Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Clin Pharmacol, Toronto, ON M4N 3M5, Canada
[2] Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Dermatol, Toronto, ON M4N 3M5, Canada
[3] Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med, Drug Safety Clin, Toronto, ON M4N 3M5, Canada
[4] Univ Toronto, Toronto, ON, Canada
关键词
D O I
10.1067/mjd.2002.126823
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The two major concerns. in drug safety are adverse drug reactions and drug interactions. When multiple drug therapies are prescribed, drug interactions become an important consideration for patients and physicians. The life of a drug is reviewed with emphasis on absorption, distribution, metabolism, and excretion. Pharmacokinetic and pharmacodynamic mechanisms for drug interactions are reviewed. The contributions of P-glycoprotein, pharmacogenetic variation, and genetic polymorphisms to drug interactions are highlighted. Prediction of drug interactions is possible with knowledge of which agents are likely to cause alterations in drug metabolism.
引用
收藏
页码:467 / 484
页数:18
相关论文
共 92 条
[1]  
A'Arcy P. F., 1996, MECH DRUG INTERACTIO
[2]  
ABRAMOWICZ M, 1995, MED LETT, V37, P73
[3]  
ABRAMOWICZ M, 1996, MED LETT, V38, P95
[4]  
Anastasio GD, 1997, AM FAM PHYSICIAN, V56, P883
[5]   ADVERSE DRUG-INTERACTIONS CLINICALLY IMPORTANT FOR THE DERMATOLOGIST [J].
ANDERSEN, WK ;
FEINGOLD, DS .
ARCHIVES OF DERMATOLOGY, 1995, 131 (04) :468-473
[6]   GRAPEFRUIT JUICE AND DRUGS - HOW SIGNIFICANT IS THE INTERACTION [J].
BAILEY, DG ;
ARNOLD, JMO ;
SPENCE, JD .
CLINICAL PHARMACOKINETICS, 1994, 26 (02) :91-98
[7]   Donepezil use in Alzheimer disease [J].
Barner, EL ;
Gray, SL .
ANNALS OF PHARMACOTHERAPY, 1998, 32 (01) :70-77
[8]   Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery [J].
Benet, LZ ;
Izumi, T ;
Zhang, YC ;
Silverman, JA ;
Wacher, VJ .
JOURNAL OF CONTROLLED RELEASE, 1999, 62 (1-2) :25-31
[9]   Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram [J].
Benton, RE ;
Honig, PK ;
Zamani, K ;
Cantilena, LR ;
Woosley, RL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (04) :383-388
[10]   Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions [J].
Bertz, RJ ;
Granneman, GR .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :210-258